These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Pharmacokinetics and Exposure-Response Analyses of Daratumumab in Combination Therapy Regimens for Patients with Multiple Myeloma. Xu XS; Dimopoulos MA; Sonneveld P; Ho PJ; Belch A; Leiba M; Capra M; Gomez D; Medvedova E; Iida S; Min CK; Schecter J; Jansson R; Zhang L; Sun YN; Clemens PL Adv Ther; 2018 Nov; 35(11):1859-1872. PubMed ID: 30374808 [TBL] [Abstract][Full Text] [Related]
28. EMA Review of Daratumumab for the Treatment of Adult Patients with Multiple Myeloma. Tzogani K; Penninga E; Schougaard Christiansen ML; Hovgaard D; Sarac SB; Camarero Jimenez J; Garcia I; Lafuente M; Sancho-López A; Salmonson T; Gisselbrecht C; Pignatti F Oncologist; 2018 May; 23(5):594-602. PubMed ID: 29371479 [TBL] [Abstract][Full Text] [Related]
29. Daratumumab monotherapy for relapsed/refractory multiple myeloma, focussed on clinical trial-unfit patients and subsequent therapy. Park SS; Min Byun J; Yoon SS; Kim K; Jung SH; Lee JJ; Min CK Br J Haematol; 2021 Apr; 193(1):101-112. PubMed ID: 33368165 [TBL] [Abstract][Full Text] [Related]
30. Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Standard of Care in Latin America for Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Propensity Score Matching Analysis. Hungria V; Martínez-Baños DM; Mateos MV; Dimopoulos MA; Cavo M; Heeg B; Garcia A; Lam A; Machnicki G; He J; Fernandez M Adv Ther; 2020 Dec; 37(12):4996-5009. PubMed ID: 33067698 [TBL] [Abstract][Full Text] [Related]
31. Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. Palumbo A; Chanan-Khan A; Weisel K; Nooka AK; Masszi T; Beksac M; Spicka I; Hungria V; Munder M; Mateos MV; Mark TM; Qi M; Schecter J; Amin H; Qin X; Deraedt W; Ahmadi T; Spencer A; Sonneveld P; N Engl J Med; 2016 Aug; 375(8):754-66. PubMed ID: 27557302 [TBL] [Abstract][Full Text] [Related]
32. FDA Approval Summary: Daratumumab for Treatment of Multiple Myeloma After One Prior Therapy. Bhatnagar V; Gormley NJ; Luo L; Shen YL; Sridhara R; Subramaniam S; Shen G; Ma L; Shord S; Goldberg KB; Farrell AT; McKee AE; Pazdur R Oncologist; 2017 Nov; 22(11):1347-1353. PubMed ID: 28904172 [TBL] [Abstract][Full Text] [Related]
33. [The efficacy and safety of daratumumab in relapsed and refractory multiple myeloma]. Jia YJ; Liu H; Wang LR; Wang T; Feng R; Chen YJ; Wang M; Guo HX; Wen L; Duan WB; Yang YZ; Wang FR; Chen YY; Huang XJ; Lu J Zhonghua Nei Ke Za Zhi; 2020 May; 59(5):347-352. PubMed ID: 32370462 [No Abstract] [Full Text] [Related]
34. Adjusted comparison of daratumumab monotherapy versus real-world historical control data from the Czech Republic in heavily pretreated and highly refractory multiple myeloma patients. Jelínek T; Maisnar V; Pour L; Špička I; Minařík J; Gregora E; Kessler P; Sýkora M; Fraňková H; Adamová D; Wróbel M; Mikula P; Jarkovský J; Diels J; Gatopoulou X; Veselá Š; Besson H; Brožová L; Ito T; Hájek R Curr Med Res Opin; 2018 May; 34(5):775-783. PubMed ID: 29172760 [TBL] [Abstract][Full Text] [Related]
35. Efficacy of daratumumab-based therapies in patients with relapsed, refractory multiple myeloma treated outside of clinical trials. Lakshman A; Abeykoon JP; Kumar SK; Rajkumar SV; Dingli D; Buadi FK; Gonsalves WI; Leung N; Dispenzieri A; Kourelis TV; Go RS; Lacy MQ; Hobbs MA; Lin Y; Warsame R; Lust J; Fonder AL; Hwa YL; Hayman SR; Russell SJ; Kyle RA; Gertz MA; Kapoor P Am J Hematol; 2017 Nov; 92(11):1146-1155. PubMed ID: 28799231 [TBL] [Abstract][Full Text] [Related]
36. Real-world data on the efficacy and safety of daratumumab treatment in Hungarian relapsed/refractory multiple myeloma patients. Lovas S; Varga G; Farkas P; Masszi T; Wohner N; Bereczki Á; Adamkovich N; Borbényi Z; Szomor Á; Alizadeh H; Szaleczky E; Wolf K; Schneider T; Plander M; Szendrei T; Csacsovszki O; Csukly Z; Rajnics P; Egyed M; Nagy Z; Rejtő L; Illés Á; Mikala G; Váróczy L Int J Hematol; 2019 Nov; 110(5):559-565. PubMed ID: 31392600 [TBL] [Abstract][Full Text] [Related]
37. Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma: The MANHATTAN Nonrandomized Clinical Trial. Landgren O; Hultcrantz M; Diamond B; Lesokhin AM; Mailankody S; Hassoun H; Tan C; Shah UA; Lu SX; Salcedo M; Werner K; Rispoli J; Caple J; Sams A; Verducci D; Jones K; Concepcion I; Ciardello A; Chansakul A; Schlossman J; Tavitian E; Shekarkhand T; Harrison A; Piacentini C; Rustad EH; Yellapantula V; Maclaughlan K; Maura F; Landau HJ; Scordo M; Chung DJ; Shah G; Lahoud OB; Thoren K; Murata K; Ramanathan L; Arcila ME; Ho C; Roshal M; Dogan A; Derkach A; Giralt SA; Korde N JAMA Oncol; 2021 Jun; 7(6):862-868. PubMed ID: 33856405 [TBL] [Abstract][Full Text] [Related]
38. Impact of performance status on overall survival in patients with relapsed and/or refractory multiple myeloma: Real-life outcomes of daratumumab treatment. Afram G; Gran C; Borg Bruchfeld J; Wagner AK; Hussain A; Alici E; Nahi H Eur J Haematol; 2020 Aug; 105(2):196-202. PubMed ID: 32281193 [TBL] [Abstract][Full Text] [Related]
39. A single center retrospective study of daratumumab, pomalidomide, and dexamethasone as 2nd-line therapy in multiple myeloma. Liu L; Fiala M; Gao F; King J; Goldsmith S; Wildes TM; Stockerl-Goldstein K; Vij R; Schroeder MA Leuk Lymphoma; 2021 Dec; 62(12):3043-3046. PubMed ID: 34142630 [TBL] [Abstract][Full Text] [Related]
40. Survival and treatment patterns of patients with relapsed or refractory multiple myeloma in France - a cohort study using the French National Healthcare database (SNDS). Touzeau C; Quignot N; Meng J; Jiang H; Khachatryan A; Singh M; Taieb V; Chauny JV; Désaméricq G Ann Hematol; 2021 Jul; 100(7):1825-1836. PubMed ID: 33884454 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]